Pelthos Therapeutics director files Form 3 showing no share ownership
Pelthos Therapeutics Inc. insider reporting shows that director Andrew J. Einhorn filed an initial ownership statement for the company’s stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pelthos Therapeutics Inc. insider reporting shows that director Andrew J. Einhorn filed an initial ownership statement for the company’s stock. The filing is dated for an event on 12/23/2025 and confirms his status as a director of Pelthos Therapeutics Inc. (ticker PTHS).
In this Form 3, Einhorn reports that he has no securities beneficially owned in Pelthos Therapeutics Inc. as of the event date. The filing is made by a single reporting person and indicates that there are no non-derivative or derivative equity holdings currently attributed to him.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Pelthos Therapeutics Inc. (PTHS) disclose in this Form 3?
What is the event date for this Pelthos Therapeutics (PTHS) insider ownership filing?
What is Andrew J. Einhorn’s relationship to Pelthos Therapeutics Inc. (PTHS)?
Does this Pelthos Therapeutics (PTHS) Form 3 report any derivative securities?
Is this Pelthos Therapeutics (PTHS) Form 3 filed by more than one reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.